Another vote of no-confidence in co-stimulated bispecifics
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Abstract titles reveal some of ASCO’s key datasets.